Loading...
•
Jun 30, 2021
Nkarta Q2 2021 Earnings Report
Reported financial results for the second quarter ended June 30, 2021.
Key Takeaways
Nkarta reported a net loss of $21.5 million for the second quarter of 2021. As of June 30, 2021, Nkarta had cash, cash equivalents, restricted cash and short-term investments of $280.3 million, which is expected to fund operations into at least the second half of 2023.
Initial data from NKX101 clinical trial expected by end of 2021
NKX019 patient dosing expected to start in 2H 2021
Collaboration with CRISPR Therapeutics to develop gene-edited cell therapies
New lease for commercial manufacturing center / headquarters to support rapid innovation and scaled production of NK cell therapies
Nkarta
Nkarta
Forward Guidance
Nkarta expects its current cash and cash equivalents will be sufficient to fund its current operating plan into at least the second half of 2023.